Experiences with citrate rather than heparin as an anticoagulant for 18F-FDG labeling of leukocytes

Journal of Nuclear Medicine Technology

Volumn 39, Issue 4, 2011, Pages 312-316

  Eldjarn, Charlotte ^a   Andersen, Merethe Wigen ^a   Forfang, Randi Moen ^a   Hagve, Signe E ^a   Rootwelt, Kjell ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

18F FDG labeled leukocytes; 18F FDG labeled white blood cells; Inflammation imaging; Vascular graft infection

Indexed keywords

C REACTIVE PROTEIN; CITRIC ACID; FLUORODEOXYGLUCOSE F 18; HEPARIN; SODIUM CHLORIDE;

ABDOMINAL AORTA ANEURYSM; ANEURYSM; ANTICOAGULATION; ARTICLE; CASE REPORT; CELL LABELING; CELL VIABILITY; COIL EMBOLIZATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; ILIAC ARTERY; ILIAC ARTERY ANEURYSM; IMAGE QUALITY; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE; LEUKOCYTE COUNT; MELENA; POSTOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; PYREXIA IDIOPATHICA; SEPSIS;

ANTICOAGULANTS; CELLS, CULTURED; CITRIC ACID; FLUORODEOXYGLUCOSE F18; HEPARIN; HUMANS; IMAGE ENHANCEMENT; ISOTOPE LABELING; LEUKOCYTES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY;

EID: 84855605956     PISSN: 00914916     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnmt.110.085464     Document Type: Article

References (18)

1. McAfee JG, Thakur ML. Survey of radioactive agents for in vitro labeling of phagocytic leukocytes, I: soluble agents. J Nucl Med. 1976;17:480-487.
2. 99mTchexamethylpropylene-amineoxime for labeling leucocytes and imaging inflammation. Lancet. 1986;328:946-949.
3. 18F]fluoro-2-deoxy-D-glucose as a potential in vitro agent for labelling human granulocytes for clinical studies by positron emission tomography. Int J Rad Appl Instrum B. 1992;19:183-190.
4. 18F-FDG labelling of human leukocytes. Nucl Med Commun. 2000;21:691-694.
5. 18F-FDG labelling of human leukocytes. Nucl Med Commun. 2001;22:601-602.
6. Peters AM, Saverymuttu SH. The value of indium-labelled leucocytes in clinical practice. Blood Rev. 1987;1:65-76.
7. 18F)fluorodeoxyglucose labelled leukocytes in normal human subjects. Nucl Med Commun. 2002;23:721-725.
8. 18F)fluoro-D-glucose-labeled white blood cells. Mol Imaging Biol. 2003;5:271-277.
9. 18F-FDG. J Nucl Med. 2005;46:1522-1530.
10. 111In-oxine-labeled leukocytes for detection of infection. Radiology. 2006;238:978-987.
11. 18F-FDG-labeled leukocyte PET/CT: initial experience in 21 patients. J Nucl Med. 2006;47:625-632.
12. Dumarey N. Imaging with FDG labeled leukocytes: is it clinically useful? Q J Nucl Med Mol Imaging. 2009;53:89-94.
13. 18F-FDG uptake in synthetic aortic vascular grafts on PET/CT in symptomatic and asymptomatic patients. J Nucl Med. 2008;49:1601-1605.
14. 99mTc-hexamethylpropylene amine oxime labelled leukocyte scintigraphy for an aortic graft infection. Interact Cardiovasc Thorac Surg. 2010;10:142-143.
15. 111In-leukocyte scintigraphy for suspected infection/inflammation, version 3.0. Available at: http://interactive.snm.org/docs/Leukocyte_v3.pdf. Approved June 2, 2004. Accessed October 19, 2011.
16. 99mTc-exametazime (HMPAO)-labeled leukocyte scintigraphy for suspected infection/inflammation, version 3.0. Available at: http://interactive.snm.org/docs/HMPAO_v3.pdf. Approved June 2, 2004. Accessed October 19, 2011.
17. 99mTc-HMPAO. Eur J Nucl Med Mol Imaging. 2010;37:842-848.
18. 111In-oxine. Eur J Nucl Med Mol Imaging. 2010;37:835-841.